A treatment of limb girdle muscular dystrophy type 2C/R5 being developed by Sarepta (SRPT) Therapeutics was granted FDA orphan designation, according to a post to the agency’s website.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 55% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on SRPT:
- Oppenheimer biotech analysts hold an analyst/industry conference call
- Sell Rating for Sarepta Therapeutics Amid FDA Investigation and Valuation Concerns
- FDA investigating risk of acute liver failure with Sarepta’s Elevidys
- Sarepta has little value if Elevidys withdrawn, says H.C. Wainwright
- Sarepta price target lowered to $30 from $84 at JPMorgan